LexaGene Holdings in partnership to develop new diagnostics tests for companion animals LexaGene Holdings Inc (CVE:LXG) (OTCMKTS:LXXGF) (FRA:5XS2) has partnered with Ethos Discovery to expand the test menu offerings that can be run on its MiQLab system. LexaGene said its first validated panel, namely the MiQLab Bacterial and AMR Test, was developed specifically for aiding in the diagnosis of urinary tract infections (UTI), one of the most common causes for veterinary visits in companion animals. The panel detects 94% of the pathogens that cause UTI in cats and dogs. Impressed by the coverage of tests included in LexaGenes first validated panel, Ethos Discovery was an early adopter of the MiQLab technology -- and it is now interested in expanding the use cases for the MiQLab to help in the diagnosis of other diseases. READ: LexaGene Holdings seeks to list its shares on the Nasdaq To address its needs, Ethos Discovery presented to LexaGene market opportunity assessments for sepsis, effusions, chronic|complicated wounds, pneumonia, diarrhea, joint diseases, seizures, hemangiosarcoma, and tick-borne infections.